Convergent Therapeutics, Inc.
Kyu Jun Son, MD, currently serves as Senior Director of Corporate Development at Convergent Therapeutics, Inc. Since graduating from Tufts University School of Medicine with a Doctor of Medicine (MD) in 2015, Kyu Jun Son has held various leadership positions in the pharmaceutical industry, including Director of New Product Planning at Q32 Bio Inc., and multiple roles at Sanofi Genzyme. At Sanofi, Kyu Jun Son led global marketing initiatives for Libtayo in basal cell carcinoma, contributed to oncology business development and forecasting, and developed strategies for new oncology products. Prior experience includes research at Vanderbilt University and volunteer work in health clinics in Uganda. Kyu Jun Son holds a Bachelor of Arts in Chemistry and Economics from Vanderbilt University.
This person is not in any teams
Convergent Therapeutics, Inc.
Convergent Therapeutics is a clinical-stage biotechnology company exploring the full potential of dual-targeted combination strategies to treat cancer. Convergent has developed a therapeutic platform that is capable of targeting validated and novel cancer antigens. Building on breakthrough research developed by Dr. Neil Bander at Weill Cornell Medicine, Convergent has demonstrated that dual targeting of surface cancer molecules like Prostate-Specific Membrane Antigen (PSMA) improves antitumor efficacy. By leveraging targeting agents with different bio-distributions, such as monoclonal antibodies and ligands, supra-additive therapeutic doses are delivered to tumor cells without additive toxicity to the patient.